Technology and Pipeline
Pipeline
The development of product portfolio is based on knowledge stemming from clinical development of the first product of Cellerix, Ontaril, which allowed for demonstrating the safety and high immunomodulatory potential of adult stem cells derived from adipose tissue in an autologous environment (cells from patients themselves).
eASCs as therapeutic source
eASCs have been completely characterized by Cellerix. Using preclinical and clinical studies, the Cellerix research team has shown that eASCs are safe (have no adverse effects) and non-immunogenic, and that the therapeutic effect of this product is due to a novel and different mechanism of action that modulates immune response in the body and suppresses inflammation.
Local administration
Product platform based on expanded adipose tissue-derived mesenchymal cells (eASCs) from allogeneic sources.
Systemic administration
Product platform based on expanded adipose tissue-derived mesenchymal cells (eASCs) from allogeneic sources.